Hynr-Cs-Allo
Motor Neuron Disease
Hanyang University Seoul HospitalCell therapyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Motor Neuron Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CANNABIS SATIVA SUBSP. SATIVA FLOWERING TOP Ospedale San Raffaele | Phase 2/3 | B |
Cannabis Sativa Extract Oromucosal Spray Ospedale San Raffaele | Phase 2/3 | B |
Xeomin® Allergan | Phase 2 | B |
Trimetazidine Dihydrochloride The University of Queensland | Phase 2 | B |
Tocilizumab Barrow Neurological Institute | Phase 2 | B |
View all 17 →
Same molecule, other indications
Hynr-Cs-Allo is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →